Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2023 - 2024)

Tonix Pharmaceuticals Holding has reported Short term Debt over the past 2 years, most recently at $2.8 million for Q4 2024.

  • Quarterly results put Short term Debt at $2.8 million for Q4 2024, up 20.0% from a year ago — trailing twelve months through Dec 2024 was $2.8 million (up 20.0% YoY), and the annual figure for FY2024 was $2.8 million, up 20.0%.
  • Short term Debt for Q4 2024 was $2.8 million at Tonix Pharmaceuticals Holding, roughly flat from $2.8 million in the prior quarter.
  • Over the last five years, Short term Debt for TNXP hit a ceiling of $2.8 million in Q1 2024 and a floor of $2.4 million in Q4 2023.